Atle Fund Management AB

**HealthInvest Partners AB** manages $313M across a concentrated portfolio of 39 holdings, focusing on high-growth opportunities within the biotechnology and pharmaceutical sectors. The fund exhibits significant conviction in established leaders, with top positions including LLY at $33.5M and ABBV at $24.7M. Further allocations are notable in MRK ($20.6M), TMO ($17.3M), and NBIX ($13.4M), signaling targeted exposure to differentiated drug development platforms. This structure suggests a deep, research-driven approach to capitalizing on sector-specific breakthroughs.

📌 Top Holdings